[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March 2002

Not in Our Methods, but in Our Ignorance

Arch Gen Psychiatry. 2002;59(3):279-280. doi:10.1001/archpsyc.59.3.279

THE COMMERCIAL development of a new drug product, especially one intended for the treatment of a psychiatric condition, is a costly, time-consuming, resource-demanding, and financially risky undertaking. Only a small fraction of "potentially promising" new drug candidates ever make it into phase 1 clinical trials, and an even smaller proportion gain marketing approval. Moreover, among the candidates that eventually do reach the market, only a few can be deemed truly innovative, let alone major therapeutic advances.

First Page Preview View Large
First page PDF preview
First page PDF preview
×